NO20051788L - Hydantoinderivater og deres anvendelse som TACE-inhibitorer - Google Patents

Hydantoinderivater og deres anvendelse som TACE-inhibitorer

Info

Publication number
NO20051788L
NO20051788L NO20051788A NO20051788A NO20051788L NO 20051788 L NO20051788 L NO 20051788L NO 20051788 A NO20051788 A NO 20051788A NO 20051788 A NO20051788 A NO 20051788A NO 20051788 L NO20051788 L NO 20051788L
Authority
NO
Norway
Prior art keywords
hydantoin derivatives
tace inhibitors
tace
formula
inhibitors
Prior art date
Application number
NO20051788A
Other languages
English (en)
Inventor
Howard Tucker
Jeremy Nicholas Burrows
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of NO20051788L publication Critical patent/NO20051788L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Hydantoinderivater med formel (l): formel (1) er brukbare ved inhibering av metalloproteinaser og særlig ved inhibering av TNF-a konverterende enzym (TACE).
NO20051788A 2002-09-13 2005-04-12 Hydantoinderivater og deres anvendelse som TACE-inhibitorer NO20051788L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221246.2A GB0221246D0 (en) 2002-09-13 2002-09-13 Compounds
PCT/GB2003/003914 WO2004024721A1 (en) 2002-09-13 2003-09-09 Hydantoin derivatives und deren verwendung als tace inhibitoren

Publications (1)

Publication Number Publication Date
NO20051788L true NO20051788L (no) 2005-06-13

Family

ID=9943999

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051788A NO20051788L (no) 2002-09-13 2005-04-12 Hydantoinderivater og deres anvendelse som TACE-inhibitorer

Country Status (19)

Country Link
US (2) US20060063818A1 (no)
EP (2) EP1551826A1 (no)
JP (2) JP2006507248A (no)
KR (1) KR20050042499A (no)
CN (1) CN1681804A (no)
AR (2) AR043049A1 (no)
AU (2) AU2003263347A1 (no)
BR (1) BR0314275A (no)
CA (1) CA2497571A1 (no)
GB (1) GB0221246D0 (no)
IS (1) IS7792A (no)
MX (1) MXPA05002602A (no)
NO (1) NO20051788L (no)
PL (1) PL375877A1 (no)
RU (1) RU2005106353A (no)
TW (2) TW200406398A (no)
UY (1) UY27972A1 (no)
WO (2) WO2004024721A1 (no)
ZA (1) ZA200501677B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
WO2005000309A2 (en) * 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0405101D0 (en) * 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
AU2005252178B2 (en) * 2004-06-02 2011-04-21 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
WO2006019768A1 (en) 2004-07-16 2006-02-23 Schering Corporation Hydantoin derivatives for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
PE20071240A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
TW200740769A (en) * 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
EP2041181B1 (en) * 2006-06-08 2011-05-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Specific protease inhibitors and their use in cancer therapy
EP1924556A2 (en) * 2006-06-28 2008-05-28 Teva Pharmaceutical Industries Ltd Crystalline forms of atorvastatin
TW200831488A (en) 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
EP2310369A4 (en) * 2008-06-24 2014-02-19 Valeant Pharmaceuticals Int BENZYL OXYANILID DERIVATIVES SUITABLE AS SODIUM CHANNEL MODULATORS
EP2331528B1 (en) 2008-09-24 2020-05-27 Merck Sharp & Dohme Corp. Compounds for the treatment of inflammatory disorders
US8450355B2 (en) 2008-09-24 2013-05-28 Merck Sharp & Dohme Corp. Compounds for the treatment of inflammatory diseases
US8541572B2 (en) 2008-11-10 2013-09-24 Merck Sharp & Dohme Corp. Compounds for the treatment of inflammatory disorders
US8569336B2 (en) 2008-11-10 2013-10-29 Ling Tong Compounds for the treatment of inflammatory disorders
NO2789607T3 (no) 2011-12-09 2018-07-07
JP6450323B2 (ja) 2013-01-07 2019-01-09 ユニバーシティ オブ サザン カリフォルニア デオキシウリジントリホスファターゼ阻害剤
AU2014275835B2 (en) 2013-06-07 2018-08-16 Kaken Pharmaceutical Co., Ltd. (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and drug containing same
WO2017006283A1 (en) 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2017006271A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
SI3319939T1 (sl) 2015-07-08 2025-04-30 Cv6 Therapeutics (Ni) Limited Zaviralci deoksiuridin trifosfataze, ki vsebujejo hidantoin
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US10858344B2 (en) 2016-11-23 2020-12-08 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11014924B2 (en) 2016-11-23 2021-05-25 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098208A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
US11174271B2 (en) 2016-11-23 2021-11-16 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
US11673884B2 (en) * 2019-11-14 2023-06-13 Foresee Pharmaceuticals Co., Inc. Matrix metalloproteinase (MMP) inhibitors and methods of use thereof
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2745875A (en) * 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) * 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) * 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
US3849574A (en) * 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS61212292A (ja) * 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
CA2229438C (en) * 1995-11-22 2006-01-17 Chiroscience Limited Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf)
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
JP2001503400A (ja) * 1996-10-22 2001-03-13 ファルマシア・アンド・アップジョン・カンパニー マトリックス・メタロプロテイナーゼ阻害剤としてのα―アミノスルホニルヒドロキサム酸類
WO1998050359A1 (en) * 1997-05-06 1998-11-12 Novo Nordisk A/S Novel heterocyclic compounds
PT877019E (pt) * 1997-05-09 2002-05-31 Hoechst Ag Acidos diaminocarboxilicos substituidos
EP1053226A1 (en) * 1998-02-04 2000-11-22 Novartis AG Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
WO1999058528A1 (en) * 1998-05-14 1999-11-18 Bristol-Myers Squibb Pharma Company. Substituted aryl hydroxamic acids as metalloproteinase inhibitors
WO1999065867A1 (en) * 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
DK1004578T3 (da) * 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
US6340691B1 (en) * 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
WO2001012189A1 (en) * 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
DE10047073C1 (de) * 2000-09-22 2002-01-24 Dbt Gmbh Hydraulisch schaltbares Wegeventil
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2004527511A (ja) * 2001-03-15 2004-09-09 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼ阻害剤
JP2004535411A (ja) * 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
TWI220073B (en) * 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film

Also Published As

Publication number Publication date
JP2006503829A (ja) 2006-02-02
CN1681804A (zh) 2005-10-12
US20060063818A1 (en) 2006-03-23
UY27972A1 (es) 2004-04-30
AR043049A1 (es) 2005-07-13
JP2006507248A (ja) 2006-03-02
PL375877A1 (en) 2005-12-12
AU2003263345A1 (en) 2004-04-30
MXPA05002602A (es) 2005-05-05
AU2003263347A1 (en) 2004-04-30
BR0314275A (pt) 2005-08-09
GB0221246D0 (en) 2002-10-23
EP1551826A1 (en) 2005-07-13
TW200409769A (en) 2004-06-16
WO2004024715A1 (en) 2004-03-25
ZA200501677B (en) 2005-09-12
IS7792A (is) 2005-04-11
EP1539740A1 (en) 2005-06-15
US20050256176A1 (en) 2005-11-17
KR20050042499A (ko) 2005-05-09
WO2004024721A1 (en) 2004-03-25
CA2497571A1 (en) 2004-03-25
AR041250A1 (es) 2005-05-11
TW200406398A (en) 2004-05-01
RU2005106353A (ru) 2005-10-10

Similar Documents

Publication Publication Date Title
BR0314275A (pt) Derivados de hidantoina e seu uso como inibidores de tace
AU2003282920A8 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
WO2004032846A3 (en) Triazolone and triazolethione derivatives
AU2002357312A1 (en) Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
ATE445400T1 (de) Hydantion-derivate als hemmer von matrix- metalloproteinasen
WO2003079986A3 (en) Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
NO971537L (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
NO20050199L (no) Azadisyklo-oktan og nonanderivater med DDP-IV-inhiberende aktivitet
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
NO20060168L (no) Pyridinylkarbamater som hormonsensitive lipaseinhibitorer
MEP53708A (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl) -n-methyl -amino) -anilino)-1- phenyl-methylene] -6-methoxycarbonyl -2-indolinone -monoethanesulphonate and the use thereof as a pharmaceutical composition
NO20071242L (no) Triazolpyridinylsulfanylderivater som P38-MAP-kinaseinhibitorer
ATE228998T1 (de) N-hydroxyformamid-derivate als inhibitoren von metalloproteinasen
WO2003016248A3 (en) Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
AU2003261319A8 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
WO2004108086A3 (en) HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE)
NO20012914D0 (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
DE60329326D1 (de) Tace inhibitoren
AU2003301903A1 (en) Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
NO20015892L (no) Inhibitorer av metallproteinaser
WO2003055856A3 (en) BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
AU2002346729A1 (en) Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
ATE227288T1 (de) Acetylenische ortho-sulfonamido- und phosphinsäure-amido-bicyclische heteroarylhydroxamsäure als tace-inhibitoren